News

Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis of biomarker data from an ongoing Phase 2a clinical trial. “These 6-week interim biomarker data, while early and based on…

Researchers in China used machine learning — a type of artificial intelligence in which computers detect patterns in datasets and then make predictions — to create diagnostic and prognostic models for use in idiopathic pulmonary fibrosis (IPF). Using the new models, the team observed gene activity changes suggestive of…

CS014, a treatment candidate for idiopathic pulmonary fibrosis (IPF), was found to be safe and well tolerated in healthy volunteers in a Phase 1 clinical trial, according to new data from developer Cereno Scientific. Further, the experimental medication reached levels in the bloodstream that the company predicts will…

Endeavor Biomedicines’ oral treatment candidate taladegib (ENV-101) has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis (IPF) In both regions, orphan drug status is intended to incentivize the development of medications for rare diseases. In the EU,…

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. After reviewing interim data from 24 patients treated with GRI-0621 for six weeks, an independent data monitoring…

The National Institutes of Health has awarded $219,000 to fund a project at the University of Texas at Tyler aimed at developing a treatment for radiation-induced pulmonary fibrosis (PF) which can occur after cancer radiation therapy. The study, led by Sreerama Shetty, PhD, a professor at UT Tyler, will…

Starting this week and over the coming months, the Pulmonary Fibrosis Foundation (PFF) will be hosting the PFF Walk 2025 — an annual fundraiser to support its mission of funding research, increasing advocacy, and giving support to people affected by pulmonary fibrosis (PF). The goal of PFF Walk…

Treatment with Trevi Therapeutics’ nalbuphine extended-release (ER) tablets significantly reduced daily coughing frequency in people with idiopathic pulmonary fibrosis (IPF) and chronic cough. That’s according to top-line data from the Phase 2b CORAL trial (NCT05964335), which is evaluating three doses of the experimental oral therapy against a…

Let-7, an established tumor suppressor microRNA that controls gene activity, plays a key role in lung tissue repair and the development of pulmonary fibrosis (PF), which is marked by scarring of the lungs, a study discovered. Mice lacking let-7 in lung cells spontaneously develop lung injury, demonstrating that the…

Nerandomilast, Boehringer Ingelheim’s investigational oral therapy, significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) after a year of treatment, according to final data from two Phase 3 clinical trials. FIBRONEER-IPF (NCT05321069) enrolled 1,177 IPF patients, while FIBRONEER-ILD…